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Abstract
Background: Molecularly targeted drugs promise a safer and more effective treatment modality than conventional
chemotherapy for cancer patients. However, tumors are dynamic systems that readily adapt to these agents
activating alternative survival pathways as they evolve resistant phenotypes. Combination therapies can overcome
resistance but finding the optimal combinations efficiently presents a formidable challenge. Here we introduce a new
paradigm for the design of combination therapy treatment strategies that exploits the tumor adaptive process to
identify context-dependent essential genes as druggable targets.
Methods: We have developed a framework to mine high-throughput transcriptomic data, based on differential
coexpression and Pareto optimization, to investigate drug-induced tumor adaptation. We use this approach to
identify tumor-essential genes as druggable candidates. We apply our method to a set of ER+ breast tumor samples,
collected before (n = 58) and after (n = 60) neoadjuvant treatment with the aromatase inhibitor letrozole, to
prioritize genes as targets for combination therapy with letrozole treatment. We validate letrozole-induced tumor
adaptation through coexpression and pathway analyses in an independent data set (n = 18).
Results: We find pervasive differential coexpression between the untreated and letrozole-treated tumor samples as
evidence of letrozole-induced tumor adaptation. Based on patterns of coexpression, we identify ten genes as
potential candidates for combination therapy with letrozole including EPCAM, a letrozole-induced essential gene and
a target to which drugs have already been developed as cancer therapeutics. Through replication, we validate six
letrozole-induced coexpression relationships and confirm the epithelial-to-mesenchymal transition as a process that is
upregulated in the residual tumor samples following letrozole treatment.
Conclusions: To derive the greatest benefit from molecularly targeted drugs it is critical to design combination
treatment strategies rationally. Incorporating knowledge of the tumor adaptation process into the design provides an
opportunity to match targeted drugs to the evolving tumor phenotype and surmount resistance.
Background
A great deal of effort has been directed toward the identification of molecular targets that drive oncogenesis and
the development of novel therapeutics that interact with
these targets [1-6]. However, tumor cells have a remarkable ability to adapt to such treatments through functional
redundancies and activation of compensatory signaling
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pathways that enable them to tolerate the presence of
targeted drugs. Thus, despite making important contributions to the treatment of cancer, the success of targeted
therapies has been limited by resistance.
The predominant strategy for overcoming resistance is
to combine drugs that act through ancillary mechanisms
to block the functional redundancies and compensatory
signaling pathways that serve as escape routes for cell survival. This strategy is supported by studies showing that
complex networks, including the networks of molecular
interactions that underlie biological function, are vulnerable to coordinated attacks at multiple targets [7,8], and
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by functional genomics screens with RNA-mediated interference showing that cells can be increasingly sensitized
to a molecularly targeted drug by inhibiting a second
complementary target concurrently [9]. While this strategy is intuitive and may appear straightforward, selecting
the best combination of targets to maximize tumor cell
death while minimizing collateral damage and toxicity
presents a tremendous challenge. Furthermore, it does
not take into account the evolving tumor phenotype that
emerges through the adaptation process in response to
drug perturbation.
To address this challenge we have developed a framework to identify tumor-essential genes as potential drug
targets by mining high-throughput transcriptomic data
based on coexpression patterns where coexpression serves
as a proxy for coregulation or participation in the same
biological processes [10,11]. We apply this method to
tumor samples taken from breast cancer patients undergoing preoperative letrozole treatment. This allows us to
identify essential genes in the primary and residual tumors
capturing changes in essentiality as the tumors adapt to
the drug.
Letrozole is a non-steroidal aromatase inhibitor that
binds competitively and reversibly to the aromatase
enzyme and, in effect, inhibits the production of estrogen
by blocking the conversion of androgens into estrogens.
Estrogen regulates cell growth and differentiation influencing the development and progression of breast cancer
by binding to and activating estrogen receptors (ERs). ERs
participate in cell signaling and regulate gene expression
through the activation or repression of gene transcription
[12].
Letrozole is used neoadjuvantly to reduce the volume of large operable, locally advanced, and inoperable
ER+ breast cancers in postmenopausal patients [13,14].
Efforts have been made to enhance the effects of letrozole by combining it with other drugs to reduce further
tumor burden in responders and to develop effective
treatment strategies for nonresponders [15-17]. To date,
these combinations have led to only modest increases in
clinical response. For example, combining letrozole with
the mTOR inhibitor everolimus increases response rates,
determined by clinical palpitation, at a moderately statistically significant level (P = 0.062) relative to letrozole
treatment alone [15]. This indicates that the effects of
letrozole can be enhanced by combining it with other
molecularly targeted drugs, but it also suggests that there
is room for improvement in choosing the most effective
combinations for letrozole in this setting.
Here we assess patterns of differential coexpression
among patient tumors sampled before and after letrozole
treatment. Based on these coexpression patterns we identified tumor-essential genes and letrozole-induced tumoressential genes as potential candidates for combination
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therapy with neoadjuvant letrozole treatment. We show
that coexpression is a suitable measure of tumor adaption to drug perturbation by validating letrozole-induced
coexpression relationships in an independent data set.

Methods
Data description

The initial analysis was performed with transcriptomic
data generated from core biopsies of ER+ breast tumors
at diagnosis (n = 58) and again following a 90-day course
of neoadjuvant treatment with the drug letrozole (n = 60)
[18,19]. Inclusion criteria required the samples to contain
at least 20% malignant tissue. RNA was extracted, amplified, and hybridized to Affymetrix HG-U133A GeneChip
arrays. The data are publicly available through the Gene
Expression Omnibus (GEO) database [GEO:GSE20181].
An independent data set was used for replication. The
replication data are also transcriptomic profiles generated from core biopsies of ER+ breast tumors at diagnosis (n = 18) and again following a 90-day course of
neoadjuvant treatment with the drug letrozole (n = 18)
[20]. Inclusion criteria required the samples to contain
at least 50% malignant tissue. RNA was extracted, amplified, and hybridized to Affymetrix HG-U133 Plus 2.0
GeneChip arrays. The data are publicly available through
GEO [GEO:GSE10281].
Data processing

We downloaded and processed the raw probe intensity
(CEL) files for each data set independently. We used a custom chip definition file (CDF) to ensure we were using the
most recent probe annotations and to filter the Affymetrix
probe sets to include only those probes that uniquely
map to genes [21]. Data were background corrected, normalized, and summarized using the robust multi-array
average algorithm [22] as implemented in the R statistical
language [23].
Differential expression analysis

Differential expression analysis between untreated and
letrozole-treated tumor samples was conducted using the
linear models for microarray data (limma) method [24]
implemented in the limma package in R. We chose this
method based on its robust performance across a variety of sample sizes and noise levels [25]. To correct for
multiple hypothesis testing, genes at a false discovery rate
(FDR) below 5% were considered differentially expressed
at a statistically significant level. We performed coexpression analysis on the set of differentially expressed
genes.
Differential coexpression analysis

Using the subset of genes found to be differentially
expressed by letrozole treatment, we generated two sets of
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coexpressed gene pairs, those that occur in the untreated
tumor samples and those that occur in the letrozoletreated tumor samples. To identify coexpressed gene
pairs, we calculated the first-order Spearman’s partial correlation coefficients and associated P values [26] between
the expression levels for each pairwise combination of
genes. Spearman’s correlation allows us to identify both
linear and non-linear coexpression relationships and has
been shown to outperform the more commonly applied
Pearson’s correlation coefficient at identifying coexpression relationships among genes within the same pathways
and among functionally related transcription factors [27].
Gene pairs with a coexpression P value that met an FDRbased significance threshold of α = 0.01 were retained.
This significance threshold was chosen based on simulations carried out by de la Fuente et al. [26]. To validate this
threshold for selecting coexpressed gene pairs in our data,
we used permutation testing to model the null hypothesis
that there are no coexpression relationships among genes
in these data sets (Additional file 1). Permutation tests
were designed to randomize the expression values for each
gene, across samples, within each time point. Following
randomization, we calculated coexpression as described
above and counted the number of partial correlation coefficients that met our significance threshold. This process
was repeated 1,000 times to generate a null distribution.
The observed numbers of significant coexpression relationships, for untreated and treated tumors in both data
sets, fall to the right of the upper bound in the matched
null distribution (P < 0.001) (Additional file 1) allowing
us to reject the null hypothesis by showing that more gene
pairs were coexpressed than would be expected by random chance when a significance threshold of α = 0.01 is
applied. The complete results of the coexpression analysis
are presented in Additional files 2, 3, 4, 5, 6 and 7.
Annotating coexpressed gene pairs

We annotated each gene to the Gene Ontology (GO)
biological process [28], Kyoto encyclopedia of genes and
genomes (KEGG) [29], and Reactome [30] databases
through Bioconductor. We found common processes and
pathways by intersecting the annotations for each pair of
genes.
We also evaluated each gene pair for functional relationships based on empirical data with networks from
the Integrated Multi-species Prediction (IMP) web server
[31]. These gene networks were generated as described
in Park et al. [32] and integrate data sources that include
wet biochemical evidence including the IntAct, MINT,
MIPS, and BioGRID databases. In these gene networks,
edges represent the posterior probability of a functional relationship between two genes. Therefore, each
edge is interpretable as the posterior probability, given
a large compendium of empirical data collected from
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human-derived samples, that two genes work together to
carry out a specific biological process. We overlaid our
coexpressed gene pairs onto these networks to determine
the likelihood that a functional relationship exists between
the pairs of genes we identify.
For novel gene pairs that replicate, we used IMP to predict functional relationships directly and to identify bridging genes that connect coexpressed gene pairs. For this
purpose we considered edges above a probability threshold of 0.70. This cutoff is stringent: only 0.042% of edges
in the network (141,214 / 333,452,400) have sufficient
evidence to place them above this threshold. Functional
descriptions of the genes in the results were taken from
GeneCards [33].
Pareto identification of tumor-essential genes

Studies in model organisms demonstrate that essential
genes tend to have a combination of many positive and
many negative genetic interactions [34]. Based on these
findings we used coexpression as a proxy for coregulation and we identified essential genes as those that have
many positively and many negatively coexpressed gene
partners. This presents a multi-objective optimization
problem because we were trying to maximize two variables, the number of positive partners and the number of
negative partners, simultaneously. It is unlikely that a single gene will maximize both of these objectives, so instead
of looking for a single solution, we used Pareto optimization, a multi-objective optimization algorithm, to identify
the set of genes that most closely maximize both objectives. To illustrate this, we plotted the number of positive
partners by the number of negative partners for each gene
(Figure 1) and identified the genes that fall along the leading edge of the data, termed the Pareto front. The genes
that lie along the Pareto front have more positively and
negatively coexpressed gene partners than any gene falling
to the left of this curve. We consider each of these genes
to be essential and thus a potential drug target.

Results

Letrozole induces differential coexpression in ER+ breast
tumors

Treatment with the aromatase inhibitor letrozole changes
gene expression globally, resulting in a marked downregulation of genes involved in cell-cycle processes including
mitosis and DNA metabolism and an upregulation of
genes involved in wounding and immune responses, skin
and vasculature development, and cell adhesion [19].
Building on this knowledge, using transcriptomic profiles for ER+ breast tumor biopsy samples collected before
(n = 58) and after (n = 60) a course of neoadjuvant
treatment with letrozole, we selected the subset of genes
that are differentially expressed for coexpression analysis. These data allowed us to generate two snapshots of
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Figure 1 Gene-wise patterns of connectivity reveal essential genes as potential drug targets for combination treatment with letrozole.
Using Pareto optimization we identified the set of genes that fall along the Pareto front denoted by the dashed lines in the (a) untreated and
(b) letrozole-treated tumor samples. These are the genes that have the optimal balance of positive and negative connections, a property that has
been associated with essentiality.

gene–gene relationships: those that occurred among these
genes in the untreated tumors and those that occurred
among these genes in the residual tumors, which have
adapted to tolerate the presence of the drug. We defined
coexpression as a statistically significant Spearman’s correlation coefficient in a partial correlation model. These
specifications allowed us to find both linear and nonlinear relationships and to focus on direct gene–gene
relationships by excluding gene pairs that are coexpressed
due to a common regulator.
We found considerable differential coexpression among
genes between the untreated and letrozole-treated tumor
samples. Approximately 80% of pairwise relationships
occurred in only one of the two treatment conditions
(Figure 2). Furthermore, we identified 1.26 times as many
pairwise relationships in the letrozole-treated tumor samples as in the untreated tumor samples among the same
set of genes. These dynamic coexpression relationships
provide evidence of tumor adaptation emphasizing the
context-dependent nature of gene–gene relationships and
suggesting that the functional relationships among genes
change as the tumors adapt to perturbation by the drug.
Each coexpressed gene pair has either a positive connectivity or a negative connectivity based on the sign of
the correlation coefficient that connects the two genes.
Gene pairs with positive connectivity have expression levels that are directly correlated. Gene pairs with negative
connectivity have expression levels that are inversely correlated. In agreement with previous work on coexpression
analysis among human genes [35], we identified more

coexpression relationships of positive connectivity than
negative connectivity in both the untreated and letrozoletreated tumor samples.
Among genes that have sustained coexpression relationships in both the untreated and letrozole-treated
tumor samples, the connectivity patterns were conserved,
indicating that the nature of the relationships between

Figure 2 Differential coexpression among 1,044 genes
differentially expressed by letrozole treatment in ER+ breast
tumor samples. Coexpression is calculated as the first-order
Spearman’s correlation coefficient for each pairwise combination of
genes. Approximately 80% of coexpression relationships are found in
only one of two treatment conditions and more coexpression
relationships are formed among this gene set in the presence of
letrozole. PostTx, post-treatment; PreTx, pre-treatment.
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these genes does not change in the presence of the
drug. We removed these common connections leaving
only those gene pairs that represent differential coexpression between the two treatment conditions for further
analysis.
Pairwise coexpression relationships are supported by
known biological evidence

To confirm that we had identified pairwise relationships with biological relevance we mapped each pair of
genes to the Gene Ontology (GO), KEGG, and Reactome databases. We also looked for evidence of functional
relationships by querying IMP, a web server that mines
empirical data to provide a predictive probability that
a pair of genes work together within a biological process. We found that 42% of the coexpressed gene pairs in
untreated tumors and 45% of the coexpressed gene pairs
in letrozole-treated tumors are supported by at least one
of these sources of biological evidence.
Furthermore, we looked for evidence of the biological effects of drug treatment. Among the pathway and
process databases, GO has the highest coverage for our
gene set (88%) compared to KEGG (38%) and Reactome
(35%). So we isolated GO biological process terms that
are exclusively represented by gene pairs in the letrozoletreated tumor samples. We found that these processes
correspond to both the intended effects and side effects of
the drug (Additional file 8). Examples include decreased
mitosis, bone density loss [36], hypercholesterolemia [36],
arthralgia and myalgia [37,38].
Adaptive coexpression propounds druggable targets for
combination therapy

Gene-wise analysis shows that, regardless of letrozole
treatment status, most genes have only a few coexpression partners and a propensity toward relationships of
positive connectivity while a few genes have many coexpression partners usually incorporating both positive and
negative connectivities (Figure 1). In general, genes tend
to form more coexpression relationships in the presence
of the drug with a noticeable increase in the number of
relationships of negative connectivity.
Our goal was to identify druggable targets that will synergize with neoadjuvant letrozole treatment. Our strategy
was to identify the genes that have connectivity patterns
consistent with those of essential genes because these are
the points at which the tumors are likely to be vulnerable to a targeted attack. Based on empirical data showing
a tendency for essential genes to form many relationships
of both positive and negative connectivities, termed double connectivity [34,39], we used Pareto optimization (see
Methods) to identify essential genes as those that maximize the numbers of positive and negative coexpression
relationships, simultaneously.
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We first identified genes with high double connectivity
in the untreated tumors as genes that are likely important
for maintaining the tumor phenotype in an estrogenrich environment. This gene set includes the GTPase
GTPBP4, the glycoprotein CD200, the microtubuleassociated MID1, the cadherin FAT4, and the neurofilament NEFL (Figure 1a). We see context-dependent
associations among these genes and their coexpression
partners illustrated by the tendency to form more coexpression relationships prior to letrozole treatment and to
associate with a different set of genes under each treatment condition (Figure 3).
Each gene in this set has the potential to be a druggable
target. Targeting one or more of these genes concurrently with the inhibition of estrogen signaling, through
letrozole treatment, has the potential to enhance letrozole’s ability to reduce tumor volume. There is limited
literature regarding the functional role of GTPBP4 in the
context of cancer. One report suggests that inhibition of
this gene could be effective by showing an inverse relationship between the expression level of GTPBP4 in breast
tumors carrying wild-type p53 and patient survival [40].
The other four genes in this set share coexpression relationships to form a connected subnetwork, which suggests
that targeting just one of these genes could effectively
modulate the expression of the others. Based on their
biological roles in the context of cancer, it appears that
the inhibition of CD200 and FAT4 would be effective
in reducing tumor volume. A series of studies demonstrated that overexpression of CD200 promotes tumor
growth and metastasis of breast cancer in immunocompetent mice through suppression of the immune response,
a process that can be reversed by treatment with an antiCD200 monoclonal antibody [41,42]. FAT4 is a member of
the Hippo signaling pathway and has been classified as a
putative tumor suppressor in breast cancer [43], although,
this is a context-dependent designation as it has also been
shown to play roles in tumorigenesis and planar cell polarity [44], a process linked to metastasis. FAT4 has been
recently implicated as a druggable target [45] but to date
there are no drugs that specifically target this gene.
In contrast, the downregulation or loss of MID1 and
NEFL has been associated with more aggressive disease.
MID1 was recently shown to mediate the ubiquitindependent degradation of α4 [46], a regulator of mTOR
and cell-cycle progression, which is highly expressed in
breast cancer [47]. NEFL is an independent prognostic
indicator of disease-free survival in early stage breast cancer where low expression correlates with worse outcome
[48]. Our coexpression networks show that expression of
FAT4 is positively correlated with CD200 and negatively
correlated with both MID1 and NEFL suggesting that
inhibition of FAT4 may be the optimal target for neoadjuvant co-treatment with letrozole because its modulation
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Figure 3 Coexpression subnetworks for each of the Pareto optimal genes. (a) Genes in untreated tumor samples. (b) Genes in letrozole-treated
tumor samples. Due to their numbers of positive and negative coexpression partners, GTPBP4, CD200, MID1, FAT4, and NEFL, are likely important for
maintaining the tumor phenotype in an estrogen-rich environment. Targeting one or more of these genes concurrently with letrozole treatment
may have a synergistic effect resulting in further reductions in tumor volume. Following a 90-day course of letrozole treatment, the number and
identity of coexpression partners of these genes changed, illustrating the context-dependent nature of gene–gene associations and suggesting
these genes are not as important in an estrogen-depleted environment. Dotted lines indicate negative relationships.

may downregulate CD200 while upregulating MID1 and
NEFL.
We also identified genes with high double connectivity
in the letrozole-treated tumors as genes that are essential in an estrogen-depleted environment. Targeting these
genes sequentially after estrogen signaling has been inhibited by letrozole has the potential to reduce further tumor
volume by blocking escape pathways as they emerge while
the tumors try to adapt to the drug. In the letrozoletreated tumors, the essential gene set includes the enzyme
CYB5R3, the kinase MYLK, the antigen EPCAM, the
growth factor BMP2, and the acetylhydrolase PAFAH1B3
(Figure 1b). These genes tend to have more coexpression partners following letrozole treatment relative to the
untreated tumor samples (Figure 4). And again, the set
of genes acting as coexpression partners differs following letrozole treatment, showing the context-dependent
nature of gene–gene associations.
The expression levels of CYB5R3 and MYLK are positively correlated. The CYB5R3 gene plays a functional
role in redox homeostasis by maintaining the balance of
NAD+ /NADH within cells. It has been linked to cancer
through its association with mitochondrial dysfunction
[49]. Mitochondrial dysfunction promotes tumor growth
in a condition-dependent manner [50]. MYLK is associated with breast tumor metastasis through in vitro studies
showing its role in mediating migration and invasion of

the MDA-MB-231 cell-line [51] and the intravasation of
breast cancer cells through an endothelial cell layer [52].
Inhibition of either of CYB5R3 or MYLK could be effective at halting tumor progression because the inhibition of
one of these genes should modulate the expression of the
other.
The expression levels of EPCAM and BMP2 are negatively correlated. EPCAM is a cell-adhesion molecule
that has been associated with cell signaling, proliferation, differentiation, migration and metastasis [53] and
used as a marker of both primary tumors and circulating tumor cells for patients with breast cancers and other
endothelium-derived tumors [54,55]. Silencing EPCAM
gene expression in breast tumor cell lines in vitro results
in a dramatic decrease in metabolic activity, cell migration
and invasion [56]. BMP2, a member of the TGFβ superfamily, is a target gene of ER signaling, which is downregulated in the presence of estrogen [57]. By forming a
heterodimer with BMP7, BMP2 acts as a TGFβ antagonist and prevents bone metastases in a mouse model
of breast cancer [58]. Due to the negative coexpression
relationship that exists between EPCAM and BMP2, inhibition of EPCAM may upregulate BMP2 to contribute to
the prevention of metastasis. Notably, several drugs have
been developed to target EPCAM as cancer therapeutics [59,60]. To our knowledge, the association between
PAFAH1B3 and breast cancer is novel.
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Figure 4 Coexpression subnetworks for each of the Pareto optimal genes. (a) Coexpression partners of CYB5R3, MYLK, EPCAM, BMP2, and
PAFAH1B3, prior to letrozole treatment. (b) Following letrozole treatment, the number and identity of coexpression partners of these genes
changed, illustrating the context-dependent nature of gene–gene associations and suggesting that these genes may have an important role in
maintaining the tumor phenotype in an estrogen-depleted environment. Targeting one or more of these genes sequentially following letrozole
treatment, after the tumors have adapted to the drug, may have a synergistic effect resulting in further reductions in tumor volume.

Replication highlights biologically relevant and novel
coexpression relationships

To determine if coexpression relationships induced by
letrozole treatment are generalizable, we did a replication
analysis with an independent data set. This data includes
transcriptomic profiles for 18 ER+ breast tumor biopsy
samples collected before and after a course of neoadjuvant treatment with letrozole. For consistency, we used
only the subset of genes that were differentially expressed
by letrozole treatment in both data sets resulting in a
set of 263 genes for coexpression analysis. Confirming
our earlier finding, there was patent differential coexpression among this set of genes for both data sets, with an
increase in the number of pairwise relationships among
genes in the letrozole-treated samples (Figure 5). With
fewer samples in the replication data, we had limited statistical power to detect patterns of coexpression; however,
those relationships that do replicate provide validation for
letrozole-induced tumor adaptation.
We validated six gene–gene relationships induced by
letrozole treatment (Table 1). One gene pair is supported
by strong biological evidence and the other five gene pairs
validate novel relationships. To attach functional meaning
to these novel findings we generated functional subnetworks in IMP that incorporate additional genes to make
connections between the coexpressed gene pairs. The first
validated relationship is a positive connection between the

ribonucleotide reductase RRM2 and the DNA topoisomerase TOP2A, two genes that map to the DNA replication pathway. They have a high probability of a functional
interaction in IMP (0.88) and are downregulated by letrozole treatment in agreement with the effects of blocking
ER signaling [61].
The next two validated gene pairs involve a long
non-coding RNA, LINC00341, of unknown function.
LINC00341 is coexpressed with RUNX1T1, a protooncogene and transcriptional repressor, which interacts
with DNA-bound transcription factors, and MEF2C, a
transcription factor involved in myogenesis and muscle
cell differentiation maintenance. Functionally, RUNX1T1
and MEF2C are linked through two intermediates, SIN3A
and both HDAC4 and HDAC9, all of which are transcriptional repressors (Figure 6a). This suggests that
LINC00341 is part of a complex that regulates transcription of MEF2C, a gene that has previously been shown to
be regulated by long non-coding RNAs [62].
The remaining three validated gene pairs constitute a subnetwork representative of the epithelial-tomesenchymal transition (EMT), a process associated with
wound healing and metastasis (Figure 6b). The two key
genes that complete the functional subnetwork among
these gene pairs, the glycoproteins FN1 and SPARC, are
bona fide markers of EMT [63,64]. FN1 functionally connects a pair of coexpressed glycoproteins, FBLN1 and
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(a) Discovery Data Set
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(b) Replication Data Set

Figure 5 Differential coexpression among 263 genes differentially expressed by letrozole treatment. Two independent data sets of ER+
breast tumor samples were used. Coexpression was calculated as the first-order Spearman’s correlation coefficient for each pairwise combination of
genes. In both the (a) discovery and (b) validation data sets, most coexpression relationships are unique to one of the two treatment conditions
with an increase in the number of letrozole-induced coexpressed gene pairs. PostTx, post-treatment; PreTx, pre-treatment.

FSTL1, and SPARC is connected to IGFBP7, a tumor
suppressor, which creates a functional link between a
candidate tumor suppressor, PDGFRL, and a mesenchymal factor, FSTL1. In addition to FN1 and SPARC, other
well-established EMT-associated genes are also upregulated in these tumor samples following letrozole treatment
including TWIST1, SNAI2, ZEB1, and ZEB2 [65]. We did
not identify any of these replicated coexpression relationships in the untreated tumor samples as evidence that the
residual tumor cells have undergone a functional reorganization during adaptation to tolerate the presence of the
drug.

Discussion
Here, we introduced a method to prioritize genes that
have coexpression and connectivity patterns consistent
with those of essential genes [34] as potential drug targets in the design of rational combination therapies for
the treatment of cancer. We applied this method to predict combination therapy targets based on the adaptive
response of ER+ breast tumors to neoadjuvant treatment
with the aromatase inhibitor letrozole. We used coexpression as a proxy for functional relationships and found
that adaptation to drug perturbation is evident in the differential coexpression patterns we observed between the
untreated and letrozole-treated tumor samples. This is
consistent with previous work showing that functional
relationships among genes are dependent on the cellular
state and local environment and reflected in patterns of
coexpression [10].
We confirmed that many of the coexpressed gene pairs
we identified have known biological relevance, but we also
found pairs that are not yet annotated to the same processes or pathways and do not yet have empirical evidence
that predicts a functional relationship. Perhaps the most
obvious reason for this is annotation bias, which occurs

because well-studied genes are assigned many annotations
while the understudied genes may not be annotated at
all [66,67]. In our analysis, 26% of the genes have one
or fewer annotations. Presumably, many of these genes
are multifunctional, serving to connect related biological pathways that will not be revealed through annotation
analysis alone. This is one of the reasons we incorporated IMP as a discovery tool, to move beyond curated
annotations to find functional relationships supported by
empirical data.
Repeated sampling of tumors before and after letrozole treatment allowed us to capture dynamic changes
in gene expression and coexpression, illustrating changes
in the functional relationships among genes that are
induced by the drug. In this way, the adaptive response
becomes a process that can be exploited to identify
context-dependent targets. In total, we have identified ten
Pareto optimal genes as potential targets for use in combination with letrozole. Of these genes, EPCAM stands
out because opportunely, several monoclonal antibodies
have already been developed against EPCAM as cancer
therapeutics, including the well-tolerated, fully humanized version, adecatumumab [59]. Inhibition of EPCAM
with adecatumumab has only been tested in patients with
advanced disease. As a single agent, adecatumumab shows
activity in metastatic breast cancer, but does not lead to
tumor regression [68]. The combination of docetaxel and
adecatumumab in a Phase IB trial achieved a clinical benefit, defined as a complete or partial response or stable
disease, in 44% of patients with relapsed or refractory
advanced-stage breast cancer [69].
Based on our findings, the addition of adecatumumab
following an initial period of letrozole treatment should
enhance the anti-tumor effects of letrozole alone. Suitably,
recent trials have demonstrated that patients continue to
derive a clinical benefit from neoadjuvant letrozole for
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Table 1 Replication of letrozole-induced coexpression relationships
Gene 1

Gene 2

Gene 1 expression
change

Gene 2 expression
change

PCOR coefficient
discovery data

PCOR coefficient
replication data

GO term

KEGG term

REACTOME term

IMP

RRM2

TOP2A

↓

↓

0.44

0.90

DNA replication

-

-

0.88

LINC00341

RUNX1T1

↑

↑

0.34

0.78

-

-

-

-

MN1

SPARC

↑

↑

0.45

0.76

-

-

-

-

FBLN1

FLRT2

↑

↑

0.43

0.70

-

-

-

-

MEF2C

LINC00341

↑

↑

0.37

0.66

-

-

-

-

FSTL1

PDGFRL

↑

↑

0.47

0.63

-

-

-

0.10

We identified coexpression relationships among a set of 263 genes that were differentially expressed in two independent data sets of breast tumor biopsies following 90 days of letrozole treatment. The coexpressed gene
pairs that validated are shown here with their pathway annotations and IMP score, which can be interpreted as the predictive probability that the two genes have a functional interaction based on a large compendium of
empirical data. GO, Gene Ontology; IMP, Integrated Multi-species Prediction; KEGG, Kyoto encyclopedia of genes and genomes; PCOR, Partial correlation coefficient.
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(a) LINC00341

Page 10 of 14

(b) EMT

Figure 6 Letrozole-induced tumor adaptation is validated through replication of coexpressed gene pairs in the residual tumors. To make
functional connections among gene pairs that have not been annotated to the same biological pathways, we used IMP, a web-based tool that
mines empirical data to provide a predictive probability that two genes have a functional relationship. (a) We identified a functional subnetwork
that implicates LINC00341, a long-non-coding RNA of unknown function, in ER-mediated repression. (b) We uncovered a functional subnetwork of
genes associated with the EMT, a process that promotes tumor metastasis. Dotted lines indicate coexpression relationships. Solid lines indicate
functional relationships determined by IMP with a predictive probability of at least 0.70. EMT, epithelial-to-mesenchymal transition.

up to one year of treatment [70-73], making sequential
therapy a fitting option. Moreover, metastasis is virtually
prevented in mice when treated with a murine-specific
version of adecatumumab [74], which suggests that this
combination has the potential to be a long-term treatment
strategy for the management of ER+ breast cancer as a
chronic condition in elderly patients [75].
Despite differences in inclusion criteria and the limited sample size of the replication data, we were able to
replicate six letrozole-induced coexpression relationships
as validation of letrozole-induced adaptation. Two of the
novel relationships that replicate provide clues about the
function of the uncharacterized long non-coding RNA
LINC00341. We have shown that LINC00341 is coexpressed with both RUNX1T1 and MEF2C (Figure 6a).
RUNX1T1 is part of a corepressor complex that interacts
with SIN3A in vivo [76]. SIN3A interacts with HDACs 4
and 9, specifically binding the catalytic domain of HDAC
9 in cells derived from B-cell tumors [77]. HDAC4 and
HDAC9 also physically interact with MEF2C repressing MEF2C-dependent transcription [78,79]. Inhibition
of SIN3 activity in breast cancer cells leads to the derepression of silenced genes, such as ESR1α, restoring sensitivity to tamoxifen treatment [80]. Through the same
mechanism, inhibiting HDACs in combination with letrozole is more effective at suppressing tumor growth in a

xenograft model than either treatment alone [81]. In this
context, through guilt-by-association [11], it appears that
LINC00341 may play a role in ER-mediated transcriptional repression.
We also showed that three validated gene pairs constitute a subnetwork representative of the EMT (Figure 6b).
This is in agreement with a previous study showing
that breast tumors contain cells with both epithelial and
mesenchymal markers, the latter being associated with
residual tumor following either chemotherapy or letrozole treatment in breast cancer [20]. EMT-derived cells
can differentiate into mature osteoblasts, adipocytes or
chondrocytes, and they have the ability to invade and
migrate, homing toward wound sites [82] and participating in the invasion-metastasis cascade [83]. The SPARC
and FN1 genes have an established association with EMT
[63,64]. IGFBP7, a secreted tumor suppressor, can discriminate circulating endothelial cells of cancer patients
from those of healthy donors [84] and, in this context,
it functionally connects SPARC, PDGFRL, a gene that is
highly expressed as primary melanomas transition into
metastatic melanomas [85], FSTL1, a diffusible mesenchymal factor that can independently determine the cell
fate of the endothelium [86], and MYLK, a multifunctional kinase that is involved in epithelial cell survival, is
required for epithelial wound healing, and is included in
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our list of Pareto optimal genes for the letrozole-treated
tumors.
Notably, although EPCAM was not in the subset of 263
genes, it is also a marker of EMT and circulating endothelial cells [54,87]. Suppression of EPCAM attenuates tumor
progression and downregulates transcription factors that
are involved in EMT reprogramming [88]. We have validated the EMT pathway as a biological process involved
in tumor adaptation to letrozole treatment and identified two potential targets within this pathway, MYLK and
EPCAM, in the discovery data set as letrozole-induced
essential genes, whose targeting should have a synergistic
effect with neoadjuvant letrozole treatment.
We have focused on using the adaptive process at a single treatment time point to identify a letrozole-induced
essential gene as a second target for sequential therapy.
Because tumors comprise heterogeneous cell populations,
it is likely that letrozole acts as a selective pressure,
changing the proportions of clonal populations within the
tumor, in addition to modulating gene expression within
individual cells. This combination of tumor evolution and
adaptation provides the tumor with a plethora of ways to
resist the effects of the drug. In light of this, we believe
this approach will reach its full potential when applied
serially throughout the course of treatment with the
sequential addition of drugs until the tumor has regressed
enough to be completely resected or until there is no
evidence of disease. If we can understand how relationships between genes change in response to a given treatment, we can plan interventions that will interfere with
the adaptation process, preventing the development of
resistance.

Conclusions
The advantage of molecularly targeted drugs is that they
selectively act on cancerous cells leading to fewer side
effects and better patient outcomes. However, tumors
are dynamic living systems that modulate gene expression and coexpression relationships as part of an adaptive response that facilitates robustness in the face of
these targeted perturbations. By focusing on patterns of
coexpression in breast tumors, before and after letrozole treatment, we were able to capture this adaptive
response and identify tumor-essential genes and letrozoleinduced tumor-essential genes as potential candidates for
combination therapy with neoadjuvant letrozole treatment. Given complete data sets of serially sampled tumors
throughout a course of treatment, this approach could
be an effective means of designing adaptive treatment
strategies that respect the context-dependent functions
of genes and the resilience of tumor cells, providing an
opportunity to refine further the process of personalized
medicine by pairing targeted drugs with evolving tumor
phenotypes.
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